AI in Action E100: Melissa Landon, VP & Chief Strategist at Cyclica

,  | June 23 2020 | JP Valentine

Welcome to our milestone 100th episode of AI in Action, the podcast that breaks down the hype and explores the impact that Data Science, Machine Learning and Artificial Intelligence are making on our everyday lives.

Powered by Alldus International, our goal is to share with you the insights of technologists and data science enthusiasts to showcase the excellent work that is being done within AI in the United States and Europe.

Today’s guest is Melissa Landon, VP and Chief Strategist at Cyclica. Cyclica is a Toronto-Based globally recognized biotechnology company that leverages AI and computational biophysics to reshape the drug discovery process. Cyclica’s proprietary structure-based and AI-augmented drug discovery platform includes Ligand Design for multi-targeted and multi-objective drug design, and Ligand Express for off-target profiling, systems biology linkages, and structural pharmacogenomic insights.

Taken together, Ligand Design and Ligand Express design advanced lead-like molecules that minimize unwanted off-target effects, while providing a holistic understanding of a molecule’s activity through integrated systems biology and structural pharmacogenomics. By doing more with Artificial Intelligence, Cyclica aims to revolutionize a system troubled with attrition and costly failures, accelerate the drug discovery process and develop medicines with greater precision.

In the show, Melissa will tell you about:

The fascinating work they are providing in the biotech industry 

What makes them stand out from the competition 

How they are applying Machine Learning and Data Science at Cyclica 

What attracted her to join Cyclica 

Upcoming projects & what’s in store for the future 

How AI and Data Science will continue to positively disrupt the HealthTech sector 

To find out more about Melissa and her work at Cyclica, check out the website www.cycliarx.com. You can also follow them on Twitter @cyclica or connect with Melissa on Linkedin.

What did you make of Melissa’s podcast? Where do you see the future of Artificial Intelligence in the HealthTech sector heading in the next few years? We would love to hear your thoughts on this episode, so please leave a comment below.

If you would like to hear more from AI in Action then please subscribe and don’t forget to like and share with your friends on social media.

Subscribe to The Alldus Podcast:

Welcome to our milestone 100th episode of AI in Action, the podcast that breaks down the hype and explores the impact that Data Science, Machine Learning and Artificial Intelligence are making on our everyday lives.

Powered by Alldus International, our goal is to share with you the insights of technologists and data science enthusiasts to showcase the excellent work that is being done within AI in the United States and Europe.

Today’s guest is Melissa Landon, VP and Chief Strategist at Cyclica. Cyclica is a Toronto-Based globally recognized biotechnology company that leverages AI and computational biophysics to reshape the drug discovery process. Cyclica’s proprietary structure-based and AI-augmented drug discovery platform includes Ligand Design for multi-targeted and multi-objective drug design, and Ligand Express for off-target profiling, systems biology linkages, and structural pharmacogenomic insights.

Taken together, Ligand Design and Ligand Express design advanced lead-like molecules that minimize unwanted off-target effects, while providing a holistic understanding of a molecule’s activity through integrated systems biology and structural pharmacogenomics. By doing more with Artificial Intelligence, Cyclica aims to revolutionize a system troubled with attrition and costly failures, accelerate the drug discovery process and develop medicines with greater precision.

In the show, Melissa will tell you about:

The fascinating work they are providing in the biotech industry 

What makes them stand out from the competition 

How they are applying Machine Learning and Data Science at Cyclica 

What attracted her to join Cyclica 

Upcoming projects & what’s in store for the future 

How AI and Data Science will continue to positively disrupt the HealthTech sector 

To find out more about Melissa and her work at Cyclica, check out the website www.cycliarx.com. You can also follow them on Twitter @cyclica or connect with Melissa on Linkedin.

What did you make of Melissa’s podcast? Where do you see the future of Artificial Intelligence in the HealthTech sector heading in the next few years? We would love to hear your thoughts on this episode, so please leave a comment below.

If you would like to hear more from AI in Action then please subscribe and don’t forget to like and share with your friends on social media.

Subscribe to The Alldus Podcast:

related podcasts

ServiceNow Series E147: Tej Hemantharaj, Director – Technical Lead at Fujitsu North America

 Welcome to episode 147 in our Digital Transformation series of the Alldus podcast, the show where we highlight the brightest talent and technical leadership within the ServiceNow ecosystem. Powered by Alldus International, our goal is to share with you the insights of leaders in the field to showcase the excellent work that is being…

Read More

AI in Action E502: Brian Hart, CTO at Covera Health

 Welcome to episode 502 of the AI in Action podcast, the show where we break down the hype and explore the impact that Data Science, Machine Learning and Artificial Intelligence are making on our everyday lives. Powered by Alldus International, our goal is to share with you the insights of technologists and data science…

Read More

ServiceNow Series E146: Florian Wallrodt, Senior Consultant and Product Line Lead ITSM at agineo

 Welcome to episode 146 in our Digital Transformation series of the Alldus podcast, the show where we highlight the brightest talent and technical leadership within the ServiceNow ecosystem. Powered by Alldus International, our goal is to share with you the insights of leaders in the field to showcase the excellent work that is being…

Read More